Incanthera PLC - Company Presentation at Hardman Lifescience Forum
RNS Number : 3833M
Incanthera PLC
21 September 2021



21 September 2021


Incanthera plc


("Incanthera" or the "Company")


Company Presentation


Incanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in oncology and dermatology, is pleased to announce a Company presentation at the Hardman & Co. Lifesciences forum on 23 September 2021.

Chairman, Tim McCarthy and Chief Executive Officer, Simon Ward will give a presentation on the Company's current corporate status and activities, followed by a Q & A session.

The Lifesciences evening webinar will provide the opportunity for investors to hear an update on the Company's current corporate activities on its portfolio and near to market asset, Sol, an innovative skin cancer formulation. 

The live webinar will host three companies during the event, which can be accessed live at 5.00 p.m. on Thursday 23 September.

Shareholders and potential investors can register to join the webinar for free:


A copy of this notification is available via the company's website at

The directors of the Company take responsibility for this announcement.


For further enquiries:


Incanthera plc


Tim McCarthy, Chairman


Simon Ward, Chief Executive Officer


Suzanne Brocks, Head of Communications




+44 (0) 7831 675747



+44 (0) 7747 625506



+44 (0) 7776 234600




Notes to Editors:

Incanthera is a specialist oncology company focused on transforming cancer treatment through innovative technologies in oncology and dermatology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.

The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers.

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.

Incanthera's strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

For more information on the Company please visit:







This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.